Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Coherus BioSciences : Mourns the Passing of Board Member Alan C. Mendelson - Form 8-K

10/13/2021 | 05:22pm EST

Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson

REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) - It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010.

"Alan was truly a titan of the biotech industry, without peer in his discipline, and this is such tremendous loss on so many levels for so many people," said Denny Lanfear, CEO of Coherus. "His contributions and impact on the industry through its genesis and evolution are difficult to overstate. I am honored to have had him as a decades-long personal friend, inspiring mentor, and the most trusted of advisors."

Mr. Lanfear continued: "Alan tenaciously advocated for Coherus from the start. His influence on our company is profound, and we are grateful for his wise counsel. On behalf of the entire Coherus team and Board, I offer our deep and heartfelt condolences to the Mendelson family."

Mr. Mendelson served as a partner at Latham & Watkins LLP from May 2000 to December 2020, where he held several leadership roles, including Co-Chair of the Emerging Companies Practice Group and Global Co-Chair of the Life Sciences Industry Group, and advised numerous private and public companies, primarily in the life sciences industry. Prior to joining Latham & Watkins, Mr. Mendelson was a partner at Cooley LLP from February 1980 to May 2000. From November 1995 to June 1996, he served as acting General Counsel of Cadence Design Systems Inc., a public electronic design automation software and services company. Previously, from April 1990 to April 1991, he served as secretary and acting general counsel of Amgen Inc. Mr. Mendelson previously served on the boards of directors of several public biotech companies including Aviron Inc., CV Therapeutics, Inc., QLT, Inc., and Valentis, Inc. He served as the corporate secretary for Mellanox Technologies, Ltd., Intuitive Surgical, Inc., Corvus Pharmaceuticals, Inc., Eargo, Inc. and 4D Molecular Therapeutics, Inc. In addition to his service on the Coherus board, Mr. Mendelson was General Counsel and Secretary at Blade Therapeutics and a Director of Neuvogen, Inc. He also served on the board of directors of the California Life Sciences Association and the National Kidney Foundation and the boards of trustees of the University of California, Berkeley Foundation and The Buck Institute for Research on Aging. Mr. Mendelson received a B.A. in Political Science from the University of California, Berkeley and a J.D. from Harvard Law School.

About Coherus BioSciences

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings to the health care system. For additional information, please visit www.coherus.com.

Coherus Contact Information:

Cheston Turbyfill

Vice President, Communications

IR@coherus.com

Disclaimer

Coherus BioSciences Inc. published this content on 13 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 October 2021 21:21:22 UTC.


ę Publicnow 2021
All news about COHERUS BIOSCIENCES, INC.
11/15Coherus, Junshi Say Toripalimab Gets US FDA Orphan Drug Designation for Esophageal Canc..
MT
11/15Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in ..
AQ
11/15Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce Toripalima..
CI
11/10Coherus BioSciences Announces New Employment Inducement Grants
GL
11/09HC Wainwright Adjusts Price Target on Coherus BioSciences to $30 From $36, Keeps Buy Ra..
MT
11/08COHERUS BIOSCIENCES : Q3 Earnings Snapshot
AQ
11/08Coherus BioSciences Reports Third Quarter 2021 Results - Form 8-K
PU
11/08COHERUS BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/08Coherus BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/08Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q3 Loss $-0.34, vs. Street Est of $-0.3..
MT
More news
Analyst Recommendations on COHERUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 336 M - -
Net income 2021 -188 M - -
Net cash 2021 84,8 M - -
P/E ratio 2021 -5,92x
Yield 2021 -
Capitalization 1 397 M 1 397 M -
EV / Sales 2021 3,90x
EV / Sales 2022 4,31x
Nbr of Employees 334
Free-Float 88,0%
Chart COHERUS BIOSCIENCES, INC.
Duration : Period :
Coherus BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COHERUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 18,20 $
Average target price 24,67 $
Spread / Average Target 35,5%
EPS Revisions
Managers and Directors
Denny M. Lanfear Chairman, President & Chief Executive Officer
McDavid Stilwell Chief Financial Officer
Barbara K. Finck Chief Medical Officer
Vladimir Vexler Chief Scientific Officer
Vincent R. Anicetti Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
COHERUS BIOSCIENCES, INC.4.72%1 397
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336